M16.0 M16.2 M16.3 M16.4 M16.5 M16.6 M16.7 M16.9 M17.0 M17.1 M17.2 M17.3 M17.4 M17.5
Conditions
Interventions
Group 1: We aim to include a total of 120 patients from the outpatient clinic of the CMSC with a symptomatic osteoarthritis of the shoulder, the hip, or the knee or with a symptomatic tendinopathy of
Sponsors
Charité - Universitätsmedizin BerlinCentrum für Muskuloskeletale ChirurgieCampus Charité Mitte
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Volljährige Patient*innen jeden Geschlechts, Symptomatische Gonarthrose des Hauptbelastungsbeins (Arthrosegrad I - III nach Kellgren-Lawrence bzw. OARSI-Joint Space Narrowing Score I - II), Symptomatische Coxarthrose (Arthrosegrad I - II nach Kellgren-Lawrence), Symptomatische Omarthrose (Arthrosegrad I - II nach Kellgren-Lawrence), Symptomatische Tendinopathien (Achillessehne, Bicepssehne, Patellasehne) age > 17 years, osteoarthritis of the knee (Kellgren-Lawrence I - II), osteoarthritis of the hip (Kellgren-Lawrence I - II), osteoarthritis of the shoulder (Kellgren-Lawrence I - II), symptomatic tendinopathy (achilles tendon, biceps tendon, patellar tendon)
Exclusion criteria
Exclusion criteria: General exclusion criteria: no consent in study participation, inflammatory/rheumatic disease; exclusion criteria for osteoarthritis patients: major trauma or surgery at the affected joint within the past 12 months, arthroscopy of the affected joint within the past 12 months, previous procedure at the cartilage of the affected joint within the past 12 months, previous injection therapy within the past 12 months; exclusion criteria for tendinopathy patients: surgery at the affected tendon within the past 12 months, previous injection therapy within the past 12 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Correlation between KOOS at 6 months follow-up and patients' individual cellular and molecular PRP composition | — |
Secondary
| Measure | Time frame |
|---|---|
| - individual cellular PRP composition (u. a. CD3, CD4, CD8, CD27, CD28, CD45, CD45RA, CD57, CD197 (CCR7), CD279 (PD-1), FoxP3 und Helios) - individual molecular PRP composition (u. a. TNF-a, G-CSF, IFN-?, IL-6, IL-10) - change of symptoms following PRP application (measured through KOOS, numeric rating scale, and analgesics used) - change of gait following PRP application (measured through 3D gait analysis) - change of Patient Reported Outcome Measures following PRP therapy: Promis-29, WORC Index, WOSI, DASH, SSV, DART shoulder, FFI, FAAM, FADI, ATRS, Tegner Score, OMAS, FADI, PRTEE, MEPS, SEV, SKV, KOOS, IKDC, DART knee, Lysholm-Score, DART hip, WOMAC, SHV, HOOS | — |
Countries
Germany
Contacts
Public ContactMarcel Niemann
Centrum für Muskuloskeletale ChirurgieCharité – Universitätsmedizin Berlin, Campus Virchow-Klinikum
Outcome results
None listed